Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Tennessee
Clinical trial register · United States · industry-sponsored

Clinical Trials in Tennessee, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9148 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 21 Nov 2026, 03:16 UTC
9148
Studies in scope
industry-sponsored, all four open statuses
4975
Recruiting now
open to new participants
2181
Lead sponsors
across recruiting studies
Top states
California 5328 Florida 4488 Illinois 2493 Georgia 2364 Arizona 2269

Trials with a site in Tennessee

692 of 9148 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
KPAP Adherence Crossover Study
NCT06413134Obstructive Sleep Apnea
SleepRes Inc.
Not applicable
30
Tennessee
2027-02-01
Not yet open
BioSensics
Observational
75
New York, Tennessee
2027-01-31
Recruiting
Incyte Corporation
Phase 2
40
California, Illinois, Maryland, North Carolina, Pennsylvania, Tennessee, Texas, Virginia
2026-12-14
Recruiting
Hoffmann-La Roche
Phase 2
40
California, District of Columbia, Georgia, Nebraska, New York, Tennessee, West Virginia
2026-11-30
Not yet open
Bristol-Myers Squibb
Phase 2
80
California, Florida, Illinois, Massachusetts, Oregon, Pennsylvania, Tennessee, Texas
2026-11-30
Recruiting
Sarepta Therapeutics, Inc.
Phase 4
20
Tennessee, Texas
2026-11-30
Recruiting
Solstice Oncology, Inc.
Phase 2
100
California, Florida, Illinois, Maryland, Massachusetts, New York, Ohio, Tennessee
2026-11-30
Recruiting
Hoffmann-La Roche
Phase 3
350
Tennessee
2026-11-15
Not yet open
Gedeon Richter Plc.
Phase 2
156
California, Florida, Nevada, New York, North Carolina, Tennessee
2026-11-12
Recruiting
Pelage Pharmaceuticals, Inc.
Phase 2
200
Arkansas, Georgia, New York, South Carolina, Tennessee, Texas
2026-11-10
Recruiting
Boehringer Ingelheim
Phase 1
90
Florida, Georgia, Pennsylvania, Tennessee, Texas
2026-11-10
Not yet open
Novo Nordisk A/S
Phase 3
450
California, Florida, Nevada, New York, North Carolina, South Carolina, Tennessee, Texas
2026-11-10
Recruiting
Pfizer
Phase 3
600
Florida, Minnesota, Nevada, New York, Ohio, Oregon, Tennessee, Texas
2026-11-05
Recruiting
A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.
NCT07903415Pancreatic Ductal Adenocarcinoma, Esophageal Cancer, Carcinoma, Non-Small-Cell Lung (NSCLC), Gastric Carcinoma
Pfizer
Phase 1
280
Michigan, Tennessee, Texas
2026-11-05
Recruiting
Daiichi Sankyo
Phase 3
200
Maryland, Nevada, Tennessee, Texas, Virginia
2026-11-04
Recruiting
Merck Sharp & Dohme LLC
Phase 3
2,136
Florida, Indiana, New York, South Carolina, Tennessee, Texas
2026-11-02
Recruiting
KPAP vs EPR for Comfort
NCT07530510Obstructive Sleep Apnea
SleepRes Inc.
Not applicable
24
Tennessee
2026-11-01
Recruiting
A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies
NCT07735533Lymphoma, B Cell, Lymphoma Non-Hodgkin, High Grade B Cell Lymphoma, Richter Transformation Lymphoma
Umoja Biopharma
Phase 1/2
274
California, Tennessee
2026-11
Not yet open
Microbio Co Ltd
Observational
1,500
Indiana, Maryland, New Mexico, Tennessee, Texas
2026-11
Recruiting
Faron Pharmaceuticals Ltd
Phase 2
90
California, Colorado, Connecticut, Florida, Massachusetts, North Carolina, Tennessee, Texas
2026-11
Recruiting
Early Feasibility Study of the Capstan Medical TMVR System
NCT07917208Mitral Regurgitation (MR)
Capstan Medical
Not applicable
15
California, Ohio, Tennessee
2026-11
Not yet open
IKS04 Regimen in Advanced Solid Tumors That Express CA242
NCT07738939Colorectal Cancer, Gastro Esophageal Junctional Cancer, Gastric Cancer (GC), GEJ Adenocarcinoma
Iksuda Therapeutics Ltd.
Phase 1
120
California, Massachusetts, Tennessee, Texas
2026-11
Not yet open
Pfizer
Phase 3
750
Arizona, California, Florida, Georgia, Idaho, Oregon, Tennessee, Texas
2026-10-29
Recruiting
JUR-003 in Adult Patients With Metastatic Prostate Cancer
NCT07824349Metastatic Castration Resistant Prostate Cancer, Oligometastatic Prostate Cancer (OMPC), Metastatic Hormone Sensitive Prostate Cancer
Juri Biosciences, Inc.
Phase 1
210
Michigan, New York, Tennessee, Texas
2026-10-26
Recruiting
Vogenx, Inc.
Phase 2
36
California, Colorado, Florida, Georgia, North Carolina, Pennsylvania, Tennessee, Texas
2026-10-20
Recruiting
Novartis Pharmaceuticals
Phase 2
220
California, Pennsylvania, Tennessee, Texas
2026-10-19
Recruiting
A Study of AWT020 in Participants With Advanced Solid Tumors
NCT07822919Advanced Cancers (Solid Tumors)
DrugAWT020
Anwita Biosciences
Phase 1
96
Florida, Tennessee, Virginia
2026-10-15
Recruiting
ModernaTX, Inc.
Phase 4
600
Kansas, Kentucky, North Carolina, Tennessee, Texas
2026-10-09
Recruiting
Madrigal Pharmaceuticals, Inc.
Phase 4
150
Arizona, Arkansas, California, Florida, Louisiana, North Carolina, Ohio, Tennessee
2026-10-07
Recruiting
Gilead Sciences
Phase 2
132
Colorado, Florida, Georgia, Tennessee
2026-10-01
Recruiting
Boehringer Ingelheim
Phase 1/2
55
Florida, Massachusetts, New Jersey, New York, Tennessee
2026-10-01
Not yet open
Ablative Solutions, Inc.
Phase 3
202
Tennessee
2026-10
Recruiting
Alcon Research
Phase 3
230
California, Kansas, Kentucky, Massachusetts, North Carolina, Pennsylvania, Tennessee, Texas
2026-09-30
Recruiting
Hoffmann-La Roche
Phase 3
3,900
Alabama, Connecticut, Florida, Idaho, New York, Tennessee, Virginia
2026-09-30
Recruiting
Phrontline Biopharma
Phase 1/2
150
California, Florida, New York, Pennsylvania, Tennessee, Texas, Virginia
2026-09-29
Recruiting
A Clinical Trial of NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT07441278Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
DrugNS-863
NS Pharma, Inc.
Phase 2
177
Tennessee
2026-09-28
Recruiting
Charm Therapeutics
Phase 1
40
California, Connecticut, Michigan, New York, Tennessee
2026-09-28
Recruiting
Alcon Research
Phase 3
178
Illinois, North Carolina, Tennessee, Virginia
2026-09-27
Recruiting
HMPL-A830 in Solid Tumors
NCT07718581Solid Tumor, Adult
Hutchmed
Phase 1/2
147
California, Florida, New Jersey, Tennessee, Utah
2026-09-24
Active, closed
JOURNEY LVAD: JOURNEY Left Ventricular Assist Device
NCT07363473Aortic Valve Regurgitation, Aortic Valve Disease Mixed, Aortic Insufficiency
JC Medical, Inc., an affiliate of Edwards Lifesciences LLC
Not applicable
50
Massachusetts, Tennessee
2026-09-22
Recruiting
Daiichi Sankyo
Phase 1/2
220
California, Colorado, Connecticut, Massachusetts, New York, Oregon, Tennessee, Texas
2026-09-17
Recruiting
Corvus Pharmaceuticals, Inc.
Phase 1
25
Indiana, Kentucky, Massachusetts, New York, North Dakota, Ohio, Pennsylvania, Tennessee
2026-09-17
Recruiting
Janssen Research & Development, LLC
Phase 2
100
Florida, Illinois, Indiana, Louisiana, Massachusetts, New York, Tennessee
2026-09-16
Active, closed
Johnson & Johnson Vision Care, Inc.
Not applicable
145
Florida, Illinois, New York, Ohio, Tennessee, Texas, Virginia
2026-09-10
Recruiting
Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC
NCT07813637Prostate Cancer, Castration-Resistant Prostate Cancer (CRPC), Metastatic Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer Patients
Janux Therapeutics
Phase 1
110
Tennessee
2026-09-10
Recruiting
Summit Therapeutics
Phase 2/3
800
Arizona, California, District of Columbia, Florida, Minnesota, Tennessee, Washington
2026-09-10
Recruiting
Johnson & Johnson Vision Care, Inc.
Not applicable
150
Florida, Georgia, Missouri, New York, Rhode Island, Tennessee, Texas, Virginia
2026-09-10
Recruiting
Tricuspid Regurgitation Treatment With LAPLACE Transcatheter Tricuspid Valve Replacement System
NCT07687485Severe Tricuspid Valve Regurgitation, Tricuspid Valve Regurgitation, Tricuspid Valve Disease, Cardiovascular Diseases (CVD)
Laplace Interventional, Inc
Not applicable
700
Oklahoma, Tennessee
2026-09-04
Recruiting
Astellas Pharma Global Development, Inc.
Phase 1/2
392
New York, Tennessee, Virginia
2026-09-02
Recruiting
Genentech, Inc.
Phase 4
100
Alabama, Arizona, Colorado, Florida, Georgia, Tennessee
2026-09-02
Not yet open
2-Hydroxybenzylamine (2-HOBA) Study in Early Alzheimer's Patients
NCT06432166Alzheimer Disease, Mild Cognitive Impairment
MTI Biotech Inc
Phase 1/2
48
Tennessee
2026-09-01
Recruiting
NewAmsterdam Pharma
Phase 2
400
Tennessee
2026-09
Not yet open
Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures
NCT06534502Seizures, Seizures, Focal, Seizure, Partial Onset, Seizure Disorder, Partial
Azurity Pharmaceuticals
Phase 4
40
North Carolina, Tennessee
2026-09
Recruiting
MaioRegen Prime Study for the Treatment of Deep Osteochondral Lesion of the Knee
NCT07332182Osteochondral Lesions of the Knee Joint, Osteochondritis Dissecans (OCD), Early Osteoarthritis
Fin-Ceramica Faenza Spa
Not applicable
400
California, Colorado, Illinois, Michigan, Ohio, Oregon, Tennessee, Texas
2026-09
Recruiting
Vanda Pharmaceuticals
Phase 3
150
California, Tennessee
2026-09
Recruiting
Novartis Pharmaceuticals
Phase 2
344
Arizona, Florida, Illinois, Oklahoma, Pennsylvania, Tennessee, Texas
2026-08-24
Recruiting
Pfizer
Phase 3
1,100
California, Florida, Maryland, Michigan, New Jersey, North Carolina, Oklahoma, Tennessee
2026-08-20
By invitation
Cor360: Clinician-Facing Broad-Spectrum Cardiac Phenotyping and Risk Assessment Using COR® Wearable ECG to Inform Outcomes-Oriented Care Pathways
NCT07775976Cardiovascular Diseases, Cardiovascular Diseases Risk, Cardiac Conduction System Disease, Bundle/Fascicular Abnormalities
Peerbridge Health, Inc
Observational
1,000
California, Tennessee
2026-08-20
Recruiting
Alnylam Pharmaceuticals
Phase 2
58
Florida, Indiana, Kansas, Missouri, Ohio, Tennessee, Texas, Wisconsin
2026-08-17
Recruiting
Pacritinib Effectiveness in Real-world Settings
NCT07774455Myelofibrosis (MF)
Swedish Orphan Biovitrum
Observational
60
Connecticut, Florida, Ohio, South Carolina, Tennessee
2026-08-13
Active, closed
AbbVie
Phase 1
143
Arizona, California, Louisiana, Massachusetts, North Carolina, Tennessee, Texas
2026-08-10
By invitation
Axsome Therapeutics, Inc.
Phase 3
300
Alabama, Arkansas, Florida, Mississippi, New York, South Carolina, Tennessee
2026-08-06
Recruiting
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
NCT07498335Berger Disease, Bergers Disease, IgA Nephropathy, Immunoglobulin A Nephropathy
Novartis Pharmaceuticals
Phase 3
28
New Jersey, Ohio, Oklahoma, Tennessee
2026-08-06
Recruiting
BioNTech SE
Phase 1
126
Missouri, Tennessee, Texas
2026-08-04
Recruiting
Digestive Care, Inc.
Observational
30
Colorado, District of Columbia, New York, Ohio, Oregon, Tennessee, Texas, Washington
2026-08-03
Recruiting
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
NCT07516093B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Nurix Therapeutics, Inc.
Phase 3
620
Georgia, Indiana, Tennessee, Texas, Virginia
2026-08-03
Recruiting
Cryoablation for Monomorphic Ventricular Tachycardia (VTS)
NCT07650032Ventricular Tachycardia, Sustained, Ventricular Tachycardia, Monomorphic
Adagio Medical
Not applicable
100
Arizona, California, Massachusetts, New York, Pennsylvania, South Carolina, Tennessee, Virginia
2026-08-01
By invitation
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
NCT07620574Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET)
Exelixis
Phase 3
5,000
New York, Ohio, Tennessee, Texas
2026-07-30
Recruiting
SI-B036-ST-101 in Advanced/Metastatic Solid Tumors
NCT07857616Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors, Metastatic Solid Cancers, Non Small Cell Lung Cancer
SystImmune Inc.
Phase 1
424
Connecticut, Florida, Oklahoma, Tennessee, Texas
2026-07-30
Not yet open
Evopoint Biosciences Inc.
Phase 1
24
Michigan, New York, Ohio, Oklahoma, Tennessee, Texas
2026-07-30
By invitation
Simultaneous Measurement of EpicArdial and Microvascular ResisTance Via Angiographic FLOW Study
NCT07676097Non-obstructive Coronary Disease, Acute or Chronic Coronary Artery Disease
AngioInsight
Observational
620
California, District of Columbia, Minnesota, New Jersey, New York, Ohio, Tennessee
2026-07-28
Recruiting
AstraZeneca
Phase 1/2
101
California, Colorado, Florida, Georgia, Missouri, New Jersey, Ohio, Tennessee
2026-07-27
Recruiting
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
NCT07755436Ovarian Cancer, Endometrial Cancer, Platinum-resistant Ovarian Cancer (PROC), Metastatic Ovarian Cancer
ArriVent BioPharma, Inc.
Phase 1
180
Florida, Massachusetts, Tennessee, Texas, Virginia
2026-07-23
Recruiting
Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
NCT07286292Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
Institut de Recherches Internationales Servier (I.R.I.S.)
Phase 2
10
California, Illinois, Massachusetts, Minnesota, Tennessee
2026-07-23
Recruiting
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
NCT07383506PIK3CA Mutations, Advanced Solid Tumors, Adult, Endometrial Cancer, HR Positive/HER-2 Negative Breast Cancer
Cogent Biosciences, Inc.
Phase 1
90
Arizona, California, Colorado, Florida, Massachusetts, Missouri, New Jersey, Tennessee
2026-07-23
Recruiting
Incannex Healthcare Ltd
Phase 2
120
California, Florida, Louisiana, Maryland, Ohio, South Carolina, Tennessee, Texas
2026-07-21
Recruiting
DBC-664 in Adult Patients With Solid Tumors
NCT07705035Malignant Germ Cell Tumor, Lung Adenocarcinoma, Gastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma, Urothelial Carcinoma
Duboce Biopharmaceuticals, Inc.
Phase 1
210
Colorado, Michigan, Missouri, New Jersey, New York, Tennessee, Texas
2026-07-17
Recruiting
IceCure Medical Ltd.
Not applicable
400
California, Oregon, Tennessee
2026-07-17
Recruiting
Immunomic Therapeutics, Inc.
Phase 1
60
California, Michigan, Tennessee, Texas
2026-07-14
Recruiting
argenx
Phase 2
40
California, Florida, Nevada, New York, Tennessee, Texas
2026-07-10
Recruiting
Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM
NCT07690436Transthyretin Amyloid Cardiomyopathy
AstraZeneca
Observational
500
California, Florida, Illinois, Massachusetts, Oregon, Tennessee
2026-07-08
Recruiting
Chiesi Farmaceutici S.p.A.
Phase 2
240
Alabama, Florida, Missouri, South Carolina, Tennessee, Texas
2026-07-08
Recruiting
Regeneron Pharmaceuticals
Phase 2
360
Arizona, California, Florida, Indiana, Kansas, Louisiana, Pennsylvania, Tennessee
2026-07-06
Recruiting
Axonics, Inc.
Observational
55
New York, Ohio, Tennessee, Texas
2026-07-02
Recruiting
Pfizer
Phase 1
120
Colorado, Connecticut, Florida, Georgia, Ohio, Tennessee
2026-07-01
Recruiting
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT07719361Metastatic Castration Resistant Prostate Cancer, mCRPC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostatic Neoplasms
Flare Therapeutics Inc.
Phase 1
60
California, Massachusetts, Michigan, New Jersey, South Carolina, Tennessee, Texas
2026-07-01
Not yet open
A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)
NCT07650357Advanced Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Carcinoma, Colorectal Cancer
Clasp Therapeutics, Inc.
Phase 1
140
North Carolina, Pennsylvania, Tennessee, Texas
2026-07
Recruiting
Pfizer
Phase 2
120
Alabama, California, Georgia, Illinois, Massachusetts, Nebraska, New Mexico, Tennessee
2026-06-30
Recruiting
Strand Therapeutics Inc.
Phase 1/2
220
Arizona, Massachusetts, Tennessee
2026-06-30
Recruiting
Janssen Research & Development, LLC
Phase 2
230
Arizona, California, Colorado, Missouri, Ohio, Tennessee, Utah
2026-06-30
Recruiting
FORWARD: Functional Outcomes in Real-World Treatment And Revascularization of Non-dominant and Distal M2 Occlusions
NCT07749170Acute Ischemic Stroke, Acute Ischemic Stroke (AIS) Related to a Distal Occlusion
Penumbra Inc.
Observational
250
Colorado, Connecticut, Kentucky, New York, North Carolina, Pennsylvania, South Carolina, Tennessee
2026-06-26
Recruiting
PureTech
Phase 3
1,100
California, Florida, Massachusetts, Nevada, North Carolina, Pennsylvania, South Carolina, Tennessee
2026-06-26
Recruiting
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
NCT07488923Small Cell Lung Cancer (SCLC ), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Gastroenteropancreatic NEC (GEP NEC), Neuroendocrine Prostate Cancer (NEPC)
Moonlight Bio, Inc
Phase 1
110
Missouri, New Jersey, New York, Tennessee, Texas, Washington
2026-06-23
Recruiting
AbbVie
Phase 2
94
California, Connecticut, Florida, Kansas, New York, North Carolina, Ohio, Tennessee
2026-06-23
Recruiting
OHB Pediatrics Ltd.
Phase 3
165
California, Colorado, Florida, Illinois, North Carolina, Tennessee
2026-06-23
Recruiting
A Study of MZE782 in Adults With PKU
NCT07694440Phenylketonuria (PKU)
Maze Therapeutics
Phase 2
38
California, Illinois, Indiana, Kentucky, Pennsylvania, Tennessee
2026-06-23
Recruiting
Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension
NCT07511361Hypertension, Acute Severe Hypertension, Hypertensive Emergency, Hypertensive Urgency
Kardigan, Inc.
Phase 2
140
Colorado, Florida, Illinois, Michigan, New York, Ohio, South Carolina, Tennessee
2026-06-23
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
960
California, Kentucky, New Jersey, New York, North Carolina, Ohio, Tennessee, Texas
2026-06-22
Active, closed
Averto Medical, Inc.
Not applicable
250
Florida, Ohio, South Carolina, Tennessee, Utah
2026-06-19
Recruiting
AstraZeneca
Phase 3
150
California, Georgia, Illinois, Kentucky, Nevada, South Dakota, Tennessee, Texas
2026-06-15
Recruiting
Eikon Therapeutics
Phase 2/3
750
Alabama, California, Colorado, Florida, Illinois, New Mexico, New York, Tennessee
2026-06-15
Active, closed
Essilor International
Not applicable
144
Arizona, California, Kentucky, Massachusetts, Minnesota, North Carolina, Tennessee
2026-06-12
Recruiting
Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections
NCT07220915Hypogammaglobulinemia, Autoimmune Conditions, Rheumatic Conditions, Infections
Octapharma
Phase 3
360
Arizona, Missouri, Tennessee, Texas
2026-06-10
Recruiting
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
NCT07629960Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
Blueprint Medicines Corporation
Phase 1/2
265
Florida, Louisiana, Massachusetts, Michigan, New Jersey, New York, Tennessee, Texas
2026-06-04
Recruiting
Galderma R&D
Not applicable
100
Connecticut, Florida, Georgia, Maryland, Tennessee, Texas
2026-06-03
Active, closed
Collection of Training Data for LuminX Probe AI Models
NCT07565480Data Collection for AI Training of Dental Prob
LuminX
Not applicable
150
California, Florida, Tennessee
2026-06-03
Not yet open
A Study of CS231295 in Patients With Advanced Solid Tumors
NCT07612488Advance Solid Tumors, Advanced Malignant Solid Tumors
ThalassaX Therapeutics United States Ltd
Phase 1
42
Colorado, Florida, Massachusetts, Tennessee
2026-06
Recruiting
Novo Nordisk A/S
Phase 1
114
California, Florida, Georgia, North Carolina, South Carolina, Tennessee, Texas
2026-05-29
Recruiting
A Phase 1 Study of the Safety and Tolerability of CTX-10726
NCT07419841Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC), Endometrial Cancer, Renal Cell Carcinoma (RCC)
Compass Therapeutics
Phase 1
70
Arizona, Florida, Minnesota, Nebraska, New York, Pennsylvania, South Carolina, Tennessee
2026-05-28
Recruiting
Ionis Pharmaceuticals, Inc.
Phase 1/2
32
Michigan, Minnesota, North Carolina, Pennsylvania, Tennessee, Washington
2026-05-21
Recruiting
Hoffmann-La Roche
Phase 2/3
650
Alabama, Arizona, California, Connecticut, Michigan, New Jersey, New York, Tennessee
2026-05-21
Recruiting
ConSynance Therapeutics
Phase 2
12
Tennessee
2026-05-18
Recruiting
Takeda
Phase 2
222
Arizona, California, Massachusetts, New York, Pennsylvania, Tennessee, Texas
2026-05-17
Recruiting
AbbVie
Phase 1/2
210
California, Colorado, Florida, Massachusetts, Tennessee, Texas
2026-05-15
Recruiting
Janssen Research & Development, LLC
Phase 1
320
Indiana, Michigan, New Jersey, New York, Tennessee, Texas
2026-05-13
Recruiting
A Study to Investigate Efficacy and Safety of KP-001 Compared With Placebo in Patients Aged ≥2 Years With Common VM, Common LM, or KTS/CLOVES Syndrome
NCT07285005Venous Malformations, Lymphatic Malformations, Klippel-Trenaunay Syndrome, CLOVES Syndrome
Kaken Pharmaceutical
Phase 3
150
Missouri, North Carolina, South Carolina, Tennessee, Texas, West Virginia
2026-05-13
Recruiting
Genmab
Phase 2
160
California, Colorado, Florida, Michigan, Tennessee, Texas
2026-05-11
Recruiting
A Study of TAK-505 in Adults With Solid Tumors
NCT07436728Malignant Solid Tumors
Takeda
Phase 1/2
151
California, Florida, Minnesota, New York, Ohio, Tennessee, Texas, Virginia
2026-05-11
Recruiting
AstraZeneca
Phase 2
24
Missouri, Rhode Island, Tennessee
2026-05-06
Active, closed
Bluejay Diagnostics, Inc.
Observational
450
Florida, Massachusetts, North Carolina, Tennessee, Utah
2026-05-04
Recruiting
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
NCT07519772Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse
Merck Sharp & Dohme LLC
Phase 1/2
280
California, Colorado, Ohio, Tennessee
2026-05-03
Recruiting
Boehringer Ingelheim
Phase 1
60
Connecticut, New Jersey, New York, Tennessee
2026-05-01
Recruiting
NextPoint Therapeutics, Inc.
Phase 1
81
California, Maryland, New York, Tennessee, Texas, Virginia
2026-05-01
Recruiting
Delve Bio, Inc.
Not applicable
400
California, Georgia, Maryland, Massachusetts, Tennessee
2026-05-01
Recruiting
Genentech, Inc.
Phase 1/2
260
Arizona, Connecticut, Tennessee
2026-04-29
Recruiting
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
NCT07469891Polycythemia Vera (PV), Myelofibrosis (MF), Myeloproliferative Neoplasms (MPNs), Post-Polycythemia Vera Myelofibrosis
Prelude Therapeutics Incorporated
Phase 1
100
California, Colorado, Florida, Michigan, Pennsylvania, Tennessee, Texas
2026-04-29
Recruiting
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
NCT07493512Metastatic Castration-resistant Prostate Cancer (mCRPC)
Amgen
Phase 1
40
Colorado, North Carolina, Ohio, Pennsylvania, South Dakota, Tennessee, Texas, Virginia
2026-04-28
By invitation
QED Therapeutics, a BridgeBio company
Phase 2
135
California, Colorado, District of Columbia, Maryland, Missouri, Ohio, Tennessee, Wisconsin
2026-04-23
Recruiting
A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors
NCT07612189Locally Advanced (Unresectable) or Metastatic Solid Tumors
NEOK Bio, Inc.
Phase 1
155
Florida, New York, Tennessee, Texas, Virginia
2026-04-22
Recruiting
Faeth Therapeutics
Phase 1/2
32
California, Colorado, Florida, Oregon, Tennessee, Texas
2026-04-22
Recruiting
Amgen
Phase 1
160
Arizona, Florida, Illinois, Minnesota, New York, Tennessee, Virginia
2026-04-21
Recruiting
A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors
NCT07612176Locally Advanced (Unresectable) or Metastatic Solid Tumors
NEOK Bio, Inc.
Phase 1
155
New York, Tennessee, Texas, Virginia
2026-04-21
Recruiting
Genentech, Inc.
Phase 1
93
Arizona, California, Florida, Maryland, Pennsylvania, Tennessee, Texas, Virginia
2026-04-21
Recruiting
EEG Abnormalities in Adult ICU Patients With High Risk of Delirium
NCT07485244Delirium in the Intensive Care Unit
Ceribell Inc.
Observational
100
Tennessee
2026-04-16
Active, closed
Oculis
Phase 2/3
160
California, Colorado, Florida, North Carolina, Pennsylvania, Tennessee, Virginia
2026-04-16
Recruiting
Mead Johnson Nutrition
Not applicable
214
Alabama, Arkansas, Florida, Illinois, Kentucky, North Carolina, Tennessee, Texas
2026-04-15
Recruiting
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
NCT07545811Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration-resistant Prostate Cancer
Janux Therapeutics
Phase 1
43
California, Missouri, South Carolina, Tennessee, Texas
2026-04-15
Recruiting
A Study of GEN1106 in Participants With Solid Tumors
NCT07416123Solid Tumors, Urothelial Carcinoma
Genmab
Phase 1
103
Connecticut, New York, South Carolina, Tennessee, Texas
2026-04-14
Recruiting
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
NCT07544589Colorectal Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Adenocarcinoma
Dispatch Biotherapeutics
Phase 1
66
California, Florida, Massachusetts, Ohio, Tennessee, Utah
2026-04-13
Active, closed
Novo Nordisk A/S
Phase 3
638
Alabama, California, Florida, Minnesota, New York, South Carolina, Tennessee, Texas
2026-04-13
Recruiting
Riboscience, LLC.
Phase 2
220
Maryland, Tennessee, Texas
2026-04-10
Recruiting
Janssen Research & Development, LLC
Phase 1
170
Connecticut, Florida, Massachusetts, Tennessee, Texas, Virginia
2026-04-09
Recruiting
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
NCT07403721Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
Amgen
Phase 1
464
California, Illinois, Indiana, Maine, Tennessee, Texas
2026-04-08
Recruiting
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
NCT07519655Non-Small-Cell Lung, Esophageal Cancer, Cutaneous Melanoma
Pfizer
Phase 1
250
Colorado, Connecticut, Tennessee, Virginia
2026-04-08
Recruiting
Grifols Therapeutics LLC
Phase 3
40
California, Florida, New York, North Carolina, Tennessee, Texas
2026-04-02
Not yet open
Robert Pickett
Not applicable
135
Indiana, Tennessee
2026-04-01
Recruiting
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
NCT07462377Epidermal Growth Factor, Epidermal Growth Factor Receptor, Epidermal Growth Factor Receptor Gene Mutation, Non Small Cell
EpiBiologics
Phase 1
110
California, New Jersey, New York, Tennessee, Texas
2026-03-31
Recruiting
A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
NCT07439653Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
TORL Biotherapeutics, LLC
Phase 1/2
155
California, Florida, Iowa, Kansas, Tennessee, Texas
2026-03-31
Not yet open
Resilient Pharmaceuticals
Phase 1
16
Tennessee
2026-03-29
By invitation
Aura Biosciences
Observational
100
California, Michigan, Minnesota, Oklahoma, South Carolina, Tennessee, Texas, Utah
2026-03-27
Recruiting
Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy
NCT07144319Bladder Cancer, Non-muscle Invasive Bladder Cancer
Photocure
Observational
500
Florida, Iowa, Michigan, New Jersey, Tennessee
2026-03-25
Recruiting
Merck Sharp & Dohme LLC
Phase 3
450
Massachusetts, Michigan, Pennsylvania, Tennessee, Texas, Washington
2026-03-23
Recruiting
Study in Advanced Solid Tumor Patients
NCT07300943Advanced Solid Tumor
Callio Therapeutics
Phase 1/2
306
Massachusetts, Tennessee, Texas, Utah
2026-03-19
Recruiting
IDEAYA Biosciences
Phase 1
155
California, Connecticut, Florida, Georgia, Missouri, New Jersey, New York, Tennessee
2026-03-17
Recruiting
Bristol-Myers Squibb
Phase 1/2
198
California, Illinois, Michigan, New Jersey, New York, Oregon, Tennessee, Washington
2026-03-16
Active, closed
Endometrial Cancer Vaginal Fluid Specimen Collection Study
NCT07544680Abnormal Uterine Bleeding (AUB), Endometrial Cancer, Atypical Endometrial Hyperplasia, Endometrial Hyperplasia With Atypia
Exact Sciences Corporation
Observational
4,200
Florida, Maine, Tennessee, Texas
2026-03-10
Recruiting
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
NCT07584226Advanced NRAS-Mutant Melanoma, Advanced NRAS-Mutant Solid Tumors, NRAS Mutation, NRAS G12D
Relay Therapeutics, Inc.
Phase 1/2
180
California, Colorado, Massachusetts, Michigan, New York, Tennessee, Virginia
2026-03-09
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 4
75
Illinois, New Jersey, North Carolina, Tennessee
2026-03-04
Not yet open
Invero Pharma, Inc.
Phase 3
1,436
Connecticut, Florida, Mississippi, Nebraska, New York, Ohio, Tennessee, Texas
2026-03
Recruiting
Bristol-Myers Squibb
Phase 4
35
Connecticut, New York, Oklahoma, Tennessee
2026-02-24
Recruiting
A Study of BI 3810944 in Patients With Advanced Cancer
NCT07224425Solid Tumours, Melanoma
Boehringer Ingelheim
Phase 1
69
Kentucky, Tennessee, Texas, Virginia
2026-02-24
Recruiting
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
NCT07503808Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
IDEAYA Biosciences
Phase 1
150
California, Colorado, Connecticut, Florida, Michigan, New Jersey, New York, Tennessee
2026-02-24
Recruiting
Xfibra, Inc.
Phase 1
40
Tennessee
2026-02-17
Recruiting
Zealand Pharma
Phase 3
90
Illinois, Missouri, Nebraska, New York, Pennsylvania, Tennessee
2026-02-11
Recruiting
Hoffmann-La Roche
Observational
2,000
California, Indiana, New York, North Carolina, Ohio, Pennsylvania, Rhode Island, Tennessee
2026-02-09
Recruiting
Astellas Pharma Global Development, Inc.
Phase 1/2
428
Florida, New Jersey, New York, Tennessee, Virginia
2026-02-05
Recruiting
Bristol-Myers Squibb
Phase 1/2
240
Michigan, New York, North Carolina, Ohio, Tennessee
2026-02-03
Recruiting
Alnylam Pharmaceuticals
Phase 3
125
Colorado, Illinois, Maryland, Massachusetts, Minnesota, New York, North Carolina, Tennessee
2026-02-03
Recruiting
Idoven 1903 S.L.
Observational
200,000
Tennessee
2026-02-03
Recruiting
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
NCT07121946Non-Hodgkin Lymphoma Refractory/ Relapsed, DLBCL - Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma ( FL)
LTZ Therapeutics, Inc.
Phase 1
42
California, Missouri, New York, Tennessee, Washington
2026-01-29
Recruiting
Dewpoint Therapeutics
Phase 1
60
California, Colorado, Connecticut, New York, Tennessee, Texas, Virginia
2026-01-29
Recruiting
Bristol-Myers Squibb
Phase 1
281
Massachusetts, New York, Pennsylvania, Tennessee, Texas
2026-01-15
Recruiting
Javelin Medical
Not applicable
2,000
Illinois, Massachusetts, New York, Tennessee
2026-01-09
Recruiting
Incyte Corporation
Phase 1
280
California, Michigan, Nebraska, New York, Tennessee, Texas
2026-01-08
Active, closed
JT International SA
Phase 1
55
Tennessee, Texas
2026-01-08
Recruiting
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
NCT07284433Lymphoma Diffuse Large B-cell, Leukemia and Lymphoma, Leukemia Relapse, Lymphoma Receiving CAR-T Therapy
AvenCell Therapeutics, Inc.
Phase 1/2
178
Illinois, Rhode Island, Tennessee, Texas
2026-01-06
Recruiting
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
NCT07335601MASH - Metabolic Dysfunction-Associated Steatohepatitis
Madrigal Pharmaceuticals, Inc.
Phase 2
120
California, Colorado, District of Columbia, Illinois, Minnesota, Nebraska, New York, Tennessee
2025-12-29
Recruiting
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
NCT07288359Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer
Novartis Pharmaceuticals
Phase 1/2
205
Georgia, Tennessee, Texas
2025-12-29
Recruiting
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
NCT07219407Focal Epilepsy, Epilepsy, Refractory Focal Epilepsy, Seizure
Rapport Therapeutics Inc.
Phase 2
30
Idaho, Minnesota, New York, Ohio, Pennsylvania, Tennessee, Texas
2025-12-15
Recruiting
Merck Sharp & Dohme LLC
Phase 2
180
Florida, Michigan, Missouri, New Jersey, New York, Ohio, Oregon, Tennessee
2025-12-12
Active, closed
Zealand Pharma
Phase 3
28
Minnesota, Nebraska, Ohio, Tennessee
2025-12-11
Recruiting
A Study of NTX-1472 in Social Anxiety Disorder
NCT07323784Social Anxiety Disorder (SAD)
Newleos Therapeutics, Inc.
Phase 2
100
California, Florida, Massachusetts, Nevada, New York, Tennessee, Texas
2025-12-09
Recruiting
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT07216443Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia
DrugOrca-T
Orca Biosystems, Inc.
Phase 2
130
California, Colorado, Florida, Minnesota, New Jersey, New York, Oregon, Tennessee
2025-12-09
Active, closed
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
NCT07134088Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia
Amgen
Phase 1/2
104
California, Pennsylvania, Tennessee, Washington
2025-12-08
Active, closed
Ventus Therapeutics U.S., Inc.
Phase 2
24
California, Florida, Indiana, Michigan, Missouri, New Mexico, New York, Tennessee
2025-12-03
Active, closed
Eirion Therapeutics Inc.
Phase 2
68
Florida, Louisiana, Tennessee, Texas
2025-12-03
Recruiting
GlaxoSmithKline
Phase 1
83
Florida, New York, Pennsylvania, Tennessee, Texas
2025-12-03
Active, closed
Hanmi Pharmaceutical Company Limited
Phase 2
267
California, Illinois, Iowa, North Carolina, South Carolina, Tennessee, Texas
2025-12-02
Recruiting
Dompé Farmaceutici S.p.A
Phase 3
153
Florida, Georgia, Missouri, New York, North Carolina, Tennessee, Texas
2025-12-01
Recruiting
AbbVie
Phase 2
100
California, Connecticut, Florida, Illinois, Michigan, New York, North Carolina, Tennessee
2025-12-01
Active, closed
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
NCT07288203Melanoma (Skin Cancer), Unresectable Melanoma, Metastatic Melanoma
Iovance Biotherapeutics, Inc.
Phase 2
24
Tennessee
2025-11-28
Recruiting
Merck Sharp & Dohme LLC
Phase 3
904
Alaska, California, Maine, Maryland, Minnesota, Nebraska, North Carolina, Tennessee
2025-11-26
Recruiting
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
NCT07217301IO Resistant Squamous and Nonsquamous NSCLC
Takeda
Phase 3
1,200
Arkansas, California, District of Columbia, Florida, Missouri, New York, Tennessee, Texas
2025-11-26
Recruiting
Kuros Biosurgery AG
Not applicable
126
California, Colorado, Georgia, North Carolina, Pennsylvania, Tennessee, Virginia
2025-11-25
Recruiting
Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
NCT07136181Metastatic Uveal Melanoma, Uveal Melanoma, Metastatic, Uveal Melanoma, Recurrent, Eye Cancer, Intraocular Melanoma
Novelwise Pharmaceutical Corporation
Phase 1/2
36
Arizona, Colorado, Tennessee
2025-11-20
Active, closed
Safety and Effectiveness Evaluation of the High-intensity Focused Ultrasound Device for Lifting Lax Submental and Neck Tissue
NCT07229430Skin Laxity (Submental and Neck), Facial Skin Laxity, Submental Tissue Laxity
CLASSYS Inc.
Not applicable
273
California, North Carolina, Tennessee, Washington
2025-11-18
By invitation
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
NCT07218003Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC)
Rondo Therapeutics
Phase 1
149
California, Connecticut, Michigan, New York, North Carolina, South Carolina, Tennessee, Texas
2025-11-17
Active, closed
Hoffmann-La Roche
Phase 2
193
California, Colorado, Florida, Maryland, Massachusetts, New York, Tennessee, Washington
2025-11-13
Recruiting
AstraZeneca
Phase 1/2
83
California, Florida, Illinois, Iowa, Tennessee, Texas
2025-11-12
By invitation
Rhythm Pharmaceuticals, Inc.
Phase 2
25
Colorado, Iowa, Massachusetts, New York, North Carolina, Tennessee
2025-11-10
Recruiting
Regeneron Pharmaceuticals
Observational
50
Tennessee
2025-11-10
Recruiting
A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC
NCT06699121Primary Sclerosing Cholangitis (PSC)
LISCure Biosciences
Phase 2
87
California, Colorado, Iowa, Maryland, Minnesota, Tennessee, Washington
2025-11
Recruiting
Novartis Pharmaceuticals
Phase 3
12
Georgia, New Jersey, Pennsylvania, Tennessee
2025-10-28
Active, closed
Bavarian Nordic
Phase 2
970
Iowa, Kansas, New York, North Carolina, South Carolina, Tennessee, Texas, Virginia
2025-10-27
Recruiting
Criterium, Inc.
Phase 2
120
Connecticut, Florida, New Jersey, New York, Pennsylvania, South Carolina, Tennessee, Texas
2025-10-27
Active, closed
HEAL-4: Real-World Effectiveness of 4 Amniotic Allografts Adjunctive to Standard Care in DFU, VLU, and PU
NCT07223515Diabetic Foot Ulcer (DFU), Venous Leg Ulcers (VLUs), Pressure Ulcers, Bedsores, Decubitus Ulcer
Dynamic Medical Services dba Acesso Biologics
Observational
2,000
Michigan, Tennessee
2025-10-24
Recruiting
Telios Pharma, Inc.
Phase 2
60
Tennessee
2025-10-23
Recruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
120
California, Florida, Illinois, Oregon, Pennsylvania, Tennessee, Texas, Utah
2025-10-20
Recruiting
GlaxoSmithKline
Phase 1/2
47
Colorado, Michigan, Ohio, Tennessee
2025-10-20
Recruiting
ImmunityBio, Inc.
Phase 1/2
40
Arizona, California, Georgia, Michigan, New York, Pennsylvania, Tennessee, Virginia
2025-10-15
Recruiting
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
NCT07174583Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3
IDEAYA Biosciences
Phase 1/2
262
Colorado, Florida, Indiana, Michigan, New York, Pennsylvania, Tennessee, Texas
2025-10-14
By invitation
Novel On-body Evaluation of Cardiac Health for Oncology
NCT07158450Cardiotoxicity, Heart Failure
Skribe Medical
Observational
1,000
Colorado, Florida, Illinois, Louisiana, New York, Pennsylvania, Tennessee, Virginia
2025-10-09
Active, closed
Amgen
Phase 1
60
California, Massachusetts, Minnesota, Ohio, Pennsylvania, South Carolina, Tennessee
2025-10-07
Recruiting
A Study of CTD402 in T-ALL/LBL Patients
NCT07070219Acute Lymphocytic Leukemia Refractory, Lymphoma, Lymphoblastic
Imviva Bio
Phase 1/2
118
California, Colorado, Illinois, Minnesota, New York, Tennessee, Texas
2025-10-07
Recruiting
Diality Inc.
Not applicable
50
California, New York, Tennessee, Texas, Washington
2025-10-06
Recruiting
Cullinan Therapeutics Inc.
Phase 1
36
Florida, New York, Tennessee, Texas, Utah
2025-10-01
Recruiting
Vanda Pharmaceuticals
Phase 2
160
California, Massachusetts, North Carolina, Tennessee, Virginia
2025-10
Recruiting
ModernaTX, Inc.
Phase 1/2
190
Alabama, California, Georgia, Massachusetts, New York, North Carolina, Pennsylvania, Tennessee
2025-09-30
Recruiting
TLN-372 in Advanced KRAS Mutant Solid Tumors
NCT07204340KRAS Mutant Solid Tumors
Treeline Biosciences, Inc.
Phase 1
270
Alabama, Massachusetts, Michigan, Missouri, New York, Tennessee
2025-09-29
Recruiting
Satellos Bioscience, Inc.
Phase 2
30
California, Missouri, Ohio, Tennessee
2025-09-25
Recruiting
AstraZeneca
Phase 1/2
164
California, Florida, Minnesota, New York, Ohio, South Carolina, Tennessee
2025-09-24
Recruiting
A Study of PHN-012 in Patients With Advanced Solid Tumors
NCT07127874Colon Cancer, Pancreatic Cancer, Lung Cancer (NSCLC), Advanced Cancer
Pheon Therapeutics
Phase 1
165
California, District of Columbia, Massachusetts, Missouri, North Carolina, Oregon, Tennessee, Texas
2025-09-23
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
424
Connecticut, Florida, Massachusetts, Michigan, Tennessee, Texas
2025-09-22
By invitation
Iantrek, Inc.
Observational
250
California, Florida, Georgia, Maryland, Nevada, Pennsylvania, Tennessee, Utah
2025-09-15
Active, closed
A Study in Subjects With Neurogenic Orthostatic Hypotension
NCT07089043Neurogenic Orthostatic Hypotension
CuraSen Therapeutics, Inc.
Phase 2
12
Arizona, Michigan, New Jersey, New York, Tennessee
2025-09-12
Recruiting
AMEND TS Early Feasibility Study
NCT06951672Symptomatic Functional MR 3 or Greater
Valcare Medical Ltd.
Not applicable
15
Arizona, California, Georgia, Indiana, New York, Oregon, Tennessee, Texas
2025-09-11
Recruiting
Sensor-based Congestion ALert for Events in Peritoneal Dialysis (SCALE-PD)
NCT07059962Kidney Disease, Peritoneal Dialysis (PD), End Stage Kidney Disease (ESRD)
Bodyport Inc.
Observational
125
California, Georgia, Illinois, Tennessee
2025-09-09
Recruiting
Hoffmann-La Roche
Phase 2
120
California, Tennessee, Texas, West Virginia
2025-09-09
Recruiting
Insight Molecular Diagnostics
Observational
125
California, Florida, Ohio, Pennsylvania, Tennessee, Texas, Utah
2025-09-08
Recruiting
MBX Biosciences
Phase 1
124
Florida, Kentucky, Missouri, Tennessee
2025-09-03
Recruiting
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
NCT06966024Renal Cell Carcinoma, Urothelial Carcinoma, Castration-resistant Prostate Cancer
Deciphera Pharmaceuticals, LLC
Phase 1
60
Massachusetts, Michigan, Missouri, Ohio, Pennsylvania, Tennessee, Texas
2025-08-27
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
NCT07181473Lung Cancer (NSCLC), Prostate Cancer, Esophageal Cancer, Solid Tumor Malignancies
Phrontline Biopharma
Phase 1
200
Florida, Tennessee, Texas
2025-08-25
Recruiting
Study of BHV-1300 in Graves' Disease
NCT06980649Graves Disease
Biohaven Therapeutics Ltd.
Phase 1
15
California, Florida, Georgia, North Carolina, Ohio, Tennessee, Texas
2025-08-21
Recruiting
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
NCT07090499Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer
Pfizer
Phase 1
540
California, Connecticut, Massachusetts, Tennessee, Texas
2025-08-20
Recruiting
Avenzo Therapeutics, Inc.
Phase 1/2
380
California, Connecticut, Florida, Massachusetts, New York, Ohio, Tennessee, Texas
2025-08-20
Recruiting
A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety
NCT07019922Epileptic Encephalopathy, SCN2A Encephalopathy
Praxis Precision Medicines
Phase 3
40
California, Colorado, Illinois, Ohio, Pennsylvania, Tennessee
2025-08-13
Active, closed
Gilead Sciences
Phase 1
16
California, Georgia, Tennessee
2025-08-12
Active, closed
Pfizer
Phase 1
200
California, Florida, New York, Ohio, Tennessee
2025-08-11
Recruiting
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1
52
California, Colorado, Illinois, Massachusetts, New York, Tennessee
2025-08-11
Recruiting
Saline Enhanced Radiofrequency (SERF) Needle Ablation for Refractory VT
NCT05337241Refractory Ventricular Tachycardia
Thermedical, Inc.
Not applicable
130
Alabama, Pennsylvania, South Carolina, Tennessee, Utah
2025-08-09
Recruiting
Erasca, Inc.
Phase 1
200
Tennessee, Texas, Washington
2025-08-06
Recruiting
Rise Therapeutics LLC
Phase 1
33
Colorado, Tennessee
2025-08-01
Recruiting
WRAP North America
NCT06807099Venous Stenosis, Venous Occlusion
Merit Medical Systems, Inc.
Observational
250
Alabama, Arizona, California, Florida, Kentucky, Rhode Island, South Carolina, Tennessee
2025-07-31
Recruiting
Amgen
Phase 1
434
California, Georgia, Massachusetts, Missouri, North Carolina, Pennsylvania, Tennessee, Texas
2025-07-31
Active, closed
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
NCT07021066Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma, Biliary Tract Cancer
SystImmune Inc.
Phase 1
160
Arizona, California, Colorado, Connecticut, Louisiana, Michigan, New Jersey, Tennessee
2025-07-30
Recruiting
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
NCT06858319Kidney Diseases, Kidney Diseases, Chronic, Urological Diseases, Glomerulonephritis
Novartis Pharmaceuticals
Phase 3
220
Colorado, Florida, Iowa, New York, Tennessee, Texas
2025-07-28
Recruiting
CSL Behring
Phase 3
20
California, Florida, Georgia, Michigan, Tennessee
2025-07-28
Recruiting
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
NCT07066657Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
DrugMRG007
ArriVent BioPharma, Inc.
Phase 1
572
California, Colorado, Florida, Tennessee, Texas, Virginia, Washington
2025-07-25
Active, closed
Insmed Gene Therapy LLC
Phase 1
12
Arkansas, California, Georgia, New York, Ohio, Tennessee, Virginia
2025-07-22
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
140
California, New York, North Carolina, Pennsylvania, Tennessee
2025-07-20
Active, closed
Daiichi Sankyo
Phase 1
17
California, Georgia, Nevada, North Carolina, Ohio, Tennessee
2025-07-17
Recruiting
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
NCT06994676High-risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML), AML - Acute Myeloid Leukemia, Chronic Myeloid Leukemia
Crossbow Therapeutics, Inc.
Phase 1
72
California, Florida, Illinois, Massachusetts, Missouri, New York, Pennsylvania, Tennessee
2025-07-16
Recruiting
Janssen Research & Development, LLC
Phase 1
400
Florida, New York, Tennessee, Virginia
2025-07-15
Recruiting
XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)
NCT06895070Heart Transplant, Heart Failure, Transplant; Failure, Heart
XVIVO Perfusion
Not applicable
60
California, Georgia, Illinois, Missouri, Nebraska, New York, North Carolina, Tennessee
2025-07-10
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
360
California, District of Columbia, Michigan, New York, Pennsylvania, Tennessee, Washington
2025-07-03
Not yet open
Rophibio, Inc.
Phase 3
434
Arizona, Arkansas, Pennsylvania, Tennessee, Texas
2025-07
Active, closed
Immunovant Sciences GmbH
Phase 2
180
California, Colorado, Florida, Illinois, Louisiana, New York, Pennsylvania, Tennessee
2025-06-30
Recruiting
Data Gathering for A10900
NCT07149740Retinal Disease, Healthy, Glaucoma, Corneal Diseases
Optos, PLC
Observational
180
California, Connecticut, Massachusetts, Tennessee
2025-06-26
Recruiting
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
NCT07020221Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult
Verastem, Inc.
Phase 1/2
616
California, Maryland, Massachusetts, Michigan, Missouri, New York, Pennsylvania, Tennessee
2025-06-24
Recruiting
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
NCT07082803Lymphoma, Lymphoma, Non Hodgkin
Treeline Biosciences, Inc.
Phase 1
180
California, Michigan, Missouri, New York, Pennsylvania, Tennessee, Texas
2025-06-23
Recruiting
GlaxoSmithKline
Phase 1/2
85
Arizona, Colorado, Connecticut, Minnesota, New Jersey, Tennessee
2025-06-12
Active, closed
Biogen
Phase 3
255
California, Florida, Pennsylvania, Tennessee, Virginia, Washington
2025-06-09
Recruiting
Coologics, Inc
Not applicable
55
Florida, Georgia, Idaho, Illinois, North Carolina, Tennessee, Texas
2025-05-22
Recruiting
Biogen
Phase 3
180
Alabama, California, Michigan, New York, North Carolina, Ohio, Tennessee, Texas
2025-05-22
Active, closed
A2 Biotherapeutics Inc.
Phase 1/2
240
Arizona, California, Florida, Minnesota, Missouri, New York, Ohio, Tennessee
2025-05-22
Active, closed
UroMems SAS
Not applicable
140
California, Minnesota, North Carolina, Tennessee, Texas, Virginia
2025-05-19
Recruiting
DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease
NCT06918808Perianal Fistula Due to Crohn's Disease
DrugDB-3Q
Direct Biologics, LLC
Phase 2
36
Colorado, Missouri, New York, Pennsylvania, Tennessee
2025-05-19
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 1/2
166
California, Illinois, Michigan, New York, Ohio, Pennsylvania, Tennessee, Texas
2025-05-12
Recruiting
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
NCT06846606Relapsed Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), Relapsed/Refractory AML, Relapsed Myelodysplastic Syndromes
Auron Therapeutics, Inc.
Phase 1
69
California, Florida, New York, North Carolina, Ohio, Pennsylvania, Tennessee, Texas
2025-05-01
Recruiting
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
NCT06952010Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor, Immune Sensitive Tumor
Exelixis
Phase 1
303
California, Connecticut, Florida, Massachusetts, Missouri, New York, North Carolina, Tennessee
2025-05-01
Recruiting
Gilead Sciences
Phase 1/2
100
California, Georgia, Kansas, Missouri, Tennessee, Texas, Virginia
2025-04-30
Recruiting
Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors
NCT06414460Locally Advanced/Metastatic Solid Tumors
InSilico Medicine Hong Kong Limited
Phase 1/2
146
Colorado, Connecticut, Indiana, Tennessee, Texas
2025-04-25
Recruiting
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
NCT06915753Metastatic Hepatocellular Carcinoma, Solid Tumors, Solid Tumor, Adult, FGFR Gene Amplification
Tyra Biosciences, Inc
Phase 1
125
California, Kansas, Maryland, Massachusetts, Michigan, New York, Tennessee
2025-04-24
Active, closed
MMA Embolization for Refractory Chronic Migraine
NCT06735833Migraine Disorders
Cerenovus, Part of DePuy Synthes Products, Inc.
Not applicable
31
California, Connecticut, New York, Pennsylvania, Tennessee, West Virginia
2025-04-23
By invitation
QED Therapeutics, a BridgeBio company
Phase 2/3
24
California, Colorado, District of Columbia, Maryland, Missouri, Ohio, Tennessee, Wisconsin
2025-04-22
Recruiting
Ipsen
Observational
30
California, Missouri, New York, Tennessee, Texas, Utah
2025-04-22
Active, closed
Regeneron Pharmaceuticals
Phase 2
28
California, Colorado, Kansas, Michigan, New Jersey, Tennessee, Texas, Virginia
2025-04-14
Recruiting
AbbVie
Phase 1
232
California, Illinois, Missouri, New York, Pennsylvania, Tennessee
2025-04-14
Active, closed
Hoffmann-La Roche
Phase 1
56
Arizona, Georgia, Louisiana, Nevada, Tennessee, Texas
2025-04-14
Recruiting
AbbVie
Phase 2
300
California, Florida, Illinois, Maryland, New Hampshire, Ohio, Pennsylvania, Tennessee
2025-04-11
Recruiting
Amylyx Pharmaceuticals Inc.
Phase 1
48
California, District of Columbia, Florida, Massachusetts, Minnesota, Pennsylvania, Tennessee, Texas
2025-04-07
Recruiting
CERo Therapeutics Holdings, Inc.
Phase 1
18
California, Colorado, Tennessee, Texas, Washington
2025-04-07
Active, closed
Chengdu Origen Biotechnology Co., Ltd.
Phase 1
9
Arizona, Illinois, Tennessee
2025-04-07
Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
Novartis Pharmaceuticals
Phase 1/2
280
California, Florida, Massachusetts, Missouri, New York, Tennessee, Texas, Washington
2025-04-03
Recruiting
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
NCT06917079Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1
665
California, Connecticut, Florida, Illinois, Massachusetts, New York, Tennessee, Texas
2025-03-31
Recruiting
Zona Health, Inc
Not applicable
160
California, Florida, Illinois, Kentucky, Pennsylvania, Tennessee, Texas
2025-03-27
Active, closed
Incyte Corporation
Phase 1
30
California, Colorado, District of Columbia, Florida, Maryland, New Jersey, Pennsylvania, Tennessee
2025-03-27
Recruiting
Bristol-Myers Squibb
Phase 1
437
New Jersey, Pennsylvania, Tennessee, Texas
2025-03-25
Recruiting
Marengo Therapeutics, Inc.
Phase 1/2
50
California, Massachusetts, Ohio, Tennessee, Texas
2025-03-24
Recruiting
Accent Therapeutics
Phase 1/2
218
Colorado, Florida, Michigan, Missouri, Nebraska, New York, Tennessee, Texas
2025-03-21
Recruiting
Clover Biopharmaceuticals USA, LLC
Phase 1
160
Arizona, Florida, Kentucky, Missouri, Tennessee
2025-03-21
Recruiting
Bayer
Phase 1/2
450
Alabama, California, Colorado, Florida, Massachusetts, Michigan, New York, Tennessee
2025-03-21
Recruiting
Biohaven Therapeutics Ltd.
Phase 1
140
California, Colorado, Florida, Michigan, North Carolina, Ohio, South Carolina, Tennessee
2025-03-20
Recruiting
Medtronic Cardiac Ablation Solutions
Not applicable
60
Massachusetts, New York, Ohio, Pennsylvania, Tennessee, Texas
2025-03-18
Active, closed
Ipsen
Phase 1/2
42
Michigan, Tennessee, Texas, Utah, Virginia
2025-03-14
Active, closed
Hoffmann-La Roche
Phase 4
274
California, Florida, Illinois, Massachusetts, Nevada, New Jersey, New Mexico, Tennessee
2025-03-14
Recruiting
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
NCT06950034Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2
Solu Therapeutics, Inc
Phase 1
105
California, Florida, Massachusetts, Minnesota, Oregon, Tennessee, Texas
2025-03-13
Recruiting
Iovance Biotherapeutics, Inc.
Phase 1/2
42
Colorado, North Carolina, Tennessee
2025-03-11
Active, closed
PREEMIE: Study for Treatment of PDA in Premature Infants
NCT06587282Patent Ductus Arteriosus (PDA)
Merit Medical Systems, Inc.
Not applicable
55
California, Florida, Georgia, Missouri, Tennessee, Texas, Wisconsin
2025-03-06
Recruiting
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
NCT06835569Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer), CRC (Colorectal Cancer)
Alterome Therapeutics, Inc.
Phase 1
448
Florida, Massachusetts, Missouri, New York, North Carolina, Tennessee, Texas, Virginia
2025-03-05
Active, closed
An Ophthalmic Safety Study in Patients With Breast Cancer
NCT06767462Ophthalmic Safety in Patients With Breast Cancer
AstraZeneca
Observational
160
California, Iowa, North Carolina, Pennsylvania, South Dakota, Tennessee, Texas
2025-03-05
Recruiting
Tyra Biosciences, Inc
Phase 2
92
California, Colorado, Delaware, Maryland, Missouri, North Carolina, Tennessee, Texas
2025-03-04
Active, closed
Dasher Neuroscience Inc.
Phase 2
75
California, Massachusetts, Minnesota, New York, Tennessee, Texas
2025-03-03
Recruiting
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
NCT06517875Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
GlaxoSmithKline
Phase 2
68
Michigan, New York, Tennessee, Texas, Washington
2025-02-28
Recruiting
Bayer
Phase 1
148
Alabama, California, Florida, Tennessee
2025-02-28
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
327
Colorado, Florida, Illinois, Massachusetts, New Jersey, New York, Oregon, Tennessee
2025-02-27
Recruiting
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NCT06792552Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC)
NextCure, Inc.
Phase 1
738
Florida, Georgia, Louisiana, Massachusetts, New Jersey, New York, Tennessee, Texas
2025-02-26
Recruiting
Pikavation Therapeutics, Inc.
Phase 1/2
320
California, Massachusetts, Pennsylvania, Tennessee, Texas
2025-02-20
Active, closed
Gilead Sciences
Phase 2
39
Missouri, Tennessee, Texas
2025-02-18
Recruiting
Bayer
Phase 2
111
Alabama, California, Florida, Massachusetts, Michigan, Ohio, Tennessee, Texas
2025-02-13
Active, closed
Novo Nordisk A/S
Phase 3
400
California, Connecticut, Hawaii, Kentucky, Missouri, South Carolina, Tennessee, Texas
2025-02-10
Recruiting
Cyted Health Inc
Observational
700
Tennessee
2025-02-05
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
DrugM9140
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
California, District of Columbia, Florida, South Carolina, Tennessee, Texas, Virginia
2025-01-29
Recruiting
Clinical Outcome Measure at Stryker Spine
NCT06226272Degenerative Disc Disease, Degenerative Scoliosis
VB Spine, LLC
Observational
5,222
Florida, Maine, Michigan, Ohio, Tennessee, Texas
2025-01-28
Recruiting
Validity of Viome's Oral/throat Cancer Test
NCT06174428Oral and Throat Cancer, Oropharyngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma
Viome
Observational
1,000
Missouri, Tennessee
2025-01-27
Active, closed
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
NCT06777316Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult, FGFR2 Gene Fusion/Rearrangement
Cogent Biosciences, Inc.
Phase 1/2
110
California, Florida, Illinois, Massachusetts, Minnesota, Ohio, Pennsylvania, Tennessee
2025-01-22
Recruiting
Cullinan Therapeutics Inc.
Phase 1
24
Arizona, Florida, Iowa, Massachusetts, New York, Tennessee, Texas, Utah
2025-01-21
Recruiting
Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
NCT06824064Metastatic Colorectal Cancer, Advanced Colorectal Cancer
Riboscience, LLC.
Phase 2
150
Delaware, Nevada, Tennessee, Texas
2025-01-17
Recruiting
Eli Lilly and Company
Phase 1/2
27
Maryland, Minnesota, Tennessee, Texas
2025-01-17
Active, closed
Quanta Therapeutics
Phase 1
237
Colorado, Connecticut, Florida, Michigan, North Carolina, Tennessee, Texas, Utah
2025-01-14
Recruiting
BeOne Medicines
Phase 1
695
California, Florida, Massachusetts, Missouri, New York, Pennsylvania, Tennessee, Texas
2025-01-10
Recruiting
Compugen Ltd
Phase 1
200
Connecticut, Massachusetts, Michigan, Tennessee, Texas, Virginia
2025-01-07
Active, closed
Daiichi Sankyo
Phase 2
335
Georgia, Michigan, New Jersey, New York, Tennessee, Texas
2025-01-06
Recruiting
InfasurfAero™ Versus Sham Treatment in Preterm Newborns With RDS
NCT05960929Respiratory Distress Syndrome (Neonatal), Intubation Complication, Death; Neonatal
ONY
Phase 3
220
Arizona, California, Florida, Hawaii, New Jersey, New York, Tennessee, Utah
2025-01-01
Active, closed
Boehringer Ingelheim
Phase 2
90
California, Connecticut, Florida, Missouri, Nebraska, New York, Tennessee, Texas
2024-12-30
Recruiting
Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
NCT06566079Malignant Mesothelioma, Metastatic Malignant Solid Tumor, Advanced Solid Tumor
InSilico Medicine Hong Kong Limited
Phase 1/2
160
Colorado, Illinois, Ohio, Pennsylvania, Tennessee, Texas
2024-12-27
Active, closed
Amgen
Phase 2
61
California, Colorado, Connecticut, District of Columbia, Louisiana, Michigan, Tennessee, Texas
2024-12-26
Active, closed
Merck Sharp & Dohme LLC
Phase 1
72
Florida, Georgia, Missouri, Tennessee
2024-12-20
Recruiting
PAQ Therapeutics, Inc.
Phase 1
300
California, Massachusetts, Michigan, Tennessee, Texas, Utah, Virginia
2024-12-19
Active, closed
Hoffmann-La Roche
Phase 1
75
California, Florida, Georgia, Maryland, Tennessee
2024-12-17
Recruiting
Aura Biosciences
Phase 2
24
California, Florida, Massachusetts, Michigan, Minnesota, Ohio, Oklahoma, Tennessee
2024-12-16
Active, closed
Treeline Biosciences, Inc.
Phase 1
50
California, Missouri, New York, Tennessee
2024-12-16
Recruiting
Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
NCT06274788Parenteral Nutrition Associated Liver Disease (PNALD), Essential Fatty Acid Deficiency, Malnutrition, Pediatric ALL
Fresenius Kabi
Observational
40
California, Illinois, Massachusetts, Ohio, Oklahoma, Tennessee, Texas, Washington
2024-12-15
Active, closed
Kumquat Biosciences Inc.
Phase 1
13
California, Colorado, Florida, Michigan, North Carolina, Ohio, Tennessee, Texas
2024-12-09
Active, closed
Kuros Biosurgery AG
Not applicable
60
California, Michigan, Missouri, Pennsylvania, Tennessee, Washington
2024-12-06
Recruiting
Merck Sharp & Dohme LLC
Phase 1
250
California, Florida, Missouri, Nebraska, Ohio, Oklahoma, Tennessee
2024-12-05
Recruiting
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
NCT06678659Unresectable, Locally Advanced, Metastatic Cancers, Relapsed/Refractory Lymphomas
Recursion Pharmaceuticals Inc.
Phase 1/2
310
California, Ohio, Tennessee, Utah
2024-11-21
Active, closed
Regeneron Pharmaceuticals
Phase 2
184
California, Illinois, Michigan, Ohio, Oregon, Rhode Island, South Dakota, Tennessee
2024-11-18
Recruiting
Day One Biopharmaceuticals, Inc.
Phase 1
300
Connecticut, Florida, Indiana, Michigan, New York, Oklahoma, Tennessee, Texas
2024-11-18
Recruiting
Daiichi Sankyo
Phase 1
150
Massachusetts, New York, Tennessee
2024-11-14
Recruiting
LDGraft in Single Level Anterior Lumbar Interbody Fusion (ALIF)
NCT06462729Degenerative Disc Disease, Lumbar Disc Disease, Spine Disease, Lumbar Spine Degeneration
Locate Bio Pty Ltd
Phase 1/2
40
Indiana, North Carolina, Tennessee
2024-11-12
Active, closed
Bluejay Diagnostics, Inc.
Observational
700
Florida, Massachusetts, North Carolina, Tennessee, Utah
2024-11-12
Active, closed
Noah Medical
Observational
50
Tennessee, Virginia
2024-11-08
Recruiting
FastWire REvascularisation of Extremities, (For LOWer Limbs) - FREEFLOW
NCT06492733Chronic Total Occlusion of Artery of the Extremities
Versono Medical Ltd
Not applicable
65
Delaware, Florida, Iowa, Louisiana, Michigan, Tennessee
2024-11-05
Recruiting
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
NCT06625775Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1
392
California, Florida, Indiana, Massachusetts, Missouri, New York, Tennessee, Texas
2024-10-29
Recruiting
Shanghai Allink Biotherapeutics Co., Ltd.
Phase 1/2
202
Colorado, Florida, Louisiana, Tennessee
2024-10-24
Active, closed
A Study of DM001 in Patients With Advanced Solid Tumors
NCT06475937Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Solid Carcinoma
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
Phase 1
128
Tennessee, Texas
2024-10-24
Recruiting
Pierre Fabre Medicament
Phase 1/2
140
District of Columbia, Ohio, Tennessee
2024-10-22
Recruiting
Ionis Pharmaceuticals, Inc.
Phase 1/2
48
California, Colorado, Maryland, Massachusetts, Minnesota, Pennsylvania, Tennessee, Texas
2024-10-21
By invitation
Prime Medicine, Inc.
Phase 1/2
12
California, Maryland, Tennessee
2024-10-17
Recruiting
Kyowa Kirin Co., Ltd.
Phase 1/2
39
California, Connecticut, Indiana, Minnesota, Tennessee
2024-10-09
Active, closed
Novartis Pharmaceuticals
Phase 2
203
Arizona, California, Florida, Illinois, Michigan, New York, Tennessee, Texas
2024-10-09
Active, closed
AstraZeneca
Phase 3
768
Arkansas, California, Florida, Missouri, New York, Ohio, Pennsylvania, Tennessee
2024-10-04
Recruiting
GlaxoSmithKline
Observational
300
Maryland, North Carolina, Ohio, Tennessee
2024-10-04
Recruiting
Telios Pharma, Inc.
Phase 2
66
Tennessee
2024-10-03
Active, closed
Eisai Inc.
Phase 2
105
Arizona, Connecticut, Florida, Georgia, Mississippi, Missouri, Pennsylvania, Tennessee
2024-09-30
Recruiting
Takeda
Observational
500
Florida, South Carolina, Tennessee
2024-09-25
Active, closed
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
NCT06561685Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
Eli Lilly and Company
Phase 1
340
California, Colorado, Florida, Illinois, Massachusetts, New York, Ohio, Tennessee
2024-09-19
Recruiting
Pierre Fabre Medicament
Phase 1/2
171
Tennessee, Texas
2024-09-17
Recruiting
Bone Mineral Density Agreement Study Between EOSedge™ Versus Traditional DXA
NCT06659055Healthy, Indicated for EOSedge Imaging
Alphatec Spine, Inc.
Not applicable
214
Arizona, California, Tennessee, Virginia
2024-09-11
Recruiting
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
NCT06393738Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Arvinas Inc.
Phase 1
329
Connecticut, Florida, Michigan, New Jersey, New York, Ohio, Tennessee, Texas
2024-09-05
Recruiting
DualityBio Inc.
Phase 1/2
360
California, District of Columbia, Florida, Illinois, North Carolina, Pennsylvania, Tennessee, Utah
2024-09-03
Recruiting
CytomX Therapeutics
Phase 1
121
California, Colorado, Pennsylvania, Tennessee, Texas
2024-08-28
Active, closed
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
NCT06449222Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers
BioNTech SE
Phase 2
83
California, Colorado, Connecticut, Illinois, Minnesota, New Jersey, New York, Tennessee
2024-08-26
Recruiting
Acepodia Biotech, Inc.
Phase 1
30
California, Colorado, Tennessee, Texas
2024-08-22
Active, closed
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
NCT06533059Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer
Alterome Therapeutics, Inc.
Phase 1
110
California, Colorado, Florida, Massachusetts, Missouri, Tennessee, Texas, Virginia
2024-08-22
Active, closed
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
NCT05589896Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Biphenotypic Leukemia
Ossium Health, Inc.
Phase 1/2
12
California, Florida, Georgia, Michigan, Oregon, Tennessee, Texas, Utah
2024-08-16
Active, closed
Iantrek, Inc.
Observational
100
Florida, Georgia, New York, Tennessee
2024-08-14
Active, closed
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
NCT06577987Advanced Solid Tumor, Metastatic Solid Tumor, Refractory Solid Tumor, Cancer
Circle Pharma
Phase 1
220
Florida, Massachusetts, Michigan, Nevada, Ohio, Oregon, Tennessee, Texas
2024-08-14
Recruiting
Sumitomo Pharma America, Inc.
Phase 1/2
120
California, Colorado, Florida, Illinois, Ohio, Tennessee, Texas, Washington
2024-08-14
Recruiting
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
NCT06545942Advanced Solid Tumor, Metastatic Solid Tumor, Prostate Cancer, Pancreas Cancer
MOMA Therapeutics
Phase 1
220
Arizona, California, Florida, Missouri, New York, Pennsylvania, South Carolina, Tennessee
2024-08-13
Active, closed
ImmunityBio, Inc.
Phase 2
34
California, Tennessee
2024-08-07
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
220
California, Colorado, Massachusetts, Michigan, New York, Ohio, Tennessee, Texas
2024-08-07
Recruiting
Innoventric Trillium™ Stent Graft Early Feasibility Study (EFS)
NCT06212193Tricuspid Regurgitation, Tricuspid Regurgitation Functional
Innoventric LTD
Not applicable
25
California, Michigan, Minnesota, New York, Ohio, Tennessee, Washington
2024-08-05
Active, closed
Palatin Technologies, Inc
Phase 2
108
Florida, Oklahoma, South Carolina, Tennessee
2024-08-05
Recruiting
Replimune, Inc.
Phase 2
60
California, Florida, Maryland, New York, Pennsylvania, Tennessee, Texas
2024-08-01
Active, closed
Palvella Therapeutics, Inc.
Phase 3
51
California, Georgia, Minnesota, New York, North Carolina, Ohio, Pennsylvania, Tennessee
2024-07-31
Active, closed
Bausch & Lomb Incorporated
Phase 4
216
California, Florida, Georgia, Indiana, Missouri, North Carolina, Tennessee
2024-07-31
Recruiting
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
144
Colorado, Florida, Missouri, Ohio, Tennessee, Texas
2024-07-24
Recruiting
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
NCT06427941Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors
BeOne Medicines
Phase 1/2
630
Alabama, Arizona, California, Illinois, New York, Pennsylvania, Tennessee, Texas
2024-07-23
Recruiting
Teva Branded Pharmaceutical Products R&D LLC
Phase 1
240
California, Florida, Illinois, Michigan, North Carolina, Ohio, Pennsylvania, Tennessee
2024-07-22
Recruiting
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
NCT06440005Cancer, Advanced Cancer, Locally Advanced Carcinoma, Metastatic Solid Tumor
Angiex, Inc.
Phase 1
80
California, Florida, Missouri, Tennessee, Texas, Virginia
2024-07-22
Recruiting
Avistone Biotechnology Co., Ltd.
Phase 1
81
California, Kentucky, Nebraska, New York, Tennessee, Washington
2024-07-08
Active, closed
Amgen
Phase 3
89
Arizona, Illinois, Michigan, Nevada, New Jersey, Oregon, Pennsylvania, Tennessee
2024-07-05
Recruiting
HPC Offered for PRESERVE Expansion
NCT07145411Bone Marrow Transplant (BMT)
Ossium Health, Inc.
Observational
10
Alabama, California, Michigan, Ohio, Tennessee
2024-06-27
Recruiting
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
NCT06501196Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Preleukemia
BlossomHill Therapeutics
Phase 1
170
California, Florida, Illinois, New York, Ohio, Tennessee, Texas, Washington
2024-06-19
Recruiting
Schrödinger, Inc.
Phase 1
52
Connecticut, Illinois, Michigan, New York, North Carolina, Ohio, Oklahoma, Tennessee
2024-06-18
Active, closed
Ocugen
Phase 3
140
Arizona, California, Florida, Pennsylvania, Tennessee, Texas, Wisconsin
2024-06-18
Recruiting
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
NCT06239194Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
ModeX Therapeutics, An OPKO Health Company
Phase 1/2
330
Colorado, Florida, Massachusetts, Tennessee, Texas
2024-06-12
Active, closed
GlaxoSmithKline
Phase 3
88
Florida, Hawaii, Kentucky, Nebraska, Tennessee, Texas, Washington
2024-06-10
Recruiting
QED Therapeutics, a BridgeBio company
Observational
150
California, Colorado, District of Columbia, Maryland, Missouri, Ohio, Tennessee, Wisconsin
2024-06-05
Active, closed
Kumquat Biosciences Inc.
Phase 1
92
Colorado, Florida, Michigan, New York, Ohio, Tennessee, Texas, Virginia
2024-06-03
Recruiting
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
130
Arizona, California, Florida, Massachusetts, Minnesota, New York, North Carolina, Tennessee
2024-05-24
Active, closed
Chimeric Therapeutics
Phase 1/2
135
Georgia, Illinois, Pennsylvania, Tennessee
2024-05-15
Active, closed
The ACES Study for Aseptic Pleural Effusion
NCT06210685Pleural Effusion
Pleural Dynamics, Inc.
Not applicable
25
Florida, Maryland, North Carolina, Tennessee
2024-05-12
Recruiting
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
NCT06425926Melanoma Stage IV, Solid Tumor
Georgiamune Inc
Phase 1/2
117
Arizona, California, Massachusetts, Montana, New York, Ohio, Tennessee, Virginia
2024-05-09
Active, closed
Servier Bio-Innovation LLC
Phase 1/2
61
Florida, Indiana, Ohio, Tennessee, Texas
2024-04-29
Active, closed
SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS
NCT06325748AML/MDS, CD33 Expressing Hematological Malignancies, FLT3 Expressing Hematological Malignancies
Senti Biosciences
Phase 1
21
California, Colorado, Florida, Tennessee, Texas
2024-04-22
Active, closed
Novartis Pharmaceuticals
Phase 1
4
Illinois, New York, Tennessee
2024-04-16
Recruiting
Daiichi Sankyo
Phase 1/2
680
California, Illinois, Minnesota, New York, Tennessee, Texas, Utah, Virginia
2024-04-10
Recruiting
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
NCT06326411Oncology, MEK Mutation, RAF Gene Mutation, Ras (KRAS or NRAS) Gene Mutation
Nested Therapeutics, Inc
Phase 1
230
California, Colorado, Connecticut, Florida, New York, Pennsylvania, Tennessee, Texas
2024-04-09
Active, closed
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
NCT06305247Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Ipsen
Phase 1/2
36
California, Connecticut, Tennessee, Virginia
2024-04-03
Active, closed
A2 Biotherapeutics Inc.
Phase 1/2
474
Arizona, California, Florida, Minnesota, Missouri, New York, Ohio, Tennessee
2024-04-03
Active, closed
Exelixis
Phase 1
429
Florida, Minnesota, New Jersey, New York, Ohio, Oklahoma, Tennessee, Texas
2024-04-03
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
43
Connecticut, Maryland, Minnesota, Missouri, North Carolina, Tennessee
2024-04-02
Recruiting
CytomX Therapeutics
Phase 1
160
Colorado, Massachusetts, New York, North Carolina, Tennessee, Texas, Virginia
2024-04-02
Recruiting
VDyne, Inc.
Not applicable
30
California, Michigan, Minnesota, New York, Ohio, Oregon, South Carolina, Tennessee
2024-04-01
Recruiting
AbbVie
Phase 1/2
76
Florida, Massachusetts, Minnesota, New York, North Carolina, Oregon, Tennessee, Washington
2024-04-01
Active, closed
OsteoGen Plug vs. Freeze-dried Bone Allograft With Collagen Barrier
NCT06447844Nonterminal Premolar Needing Extraction
McGuire Institute
Not applicable
70
Colorado, Massachusetts, Michigan, Nebraska, Tennessee, Texas, Wisconsin
2024-03-28
Active, closed
TG Therapeutics, Inc.
Observational
16
California, Georgia, Massachusetts, North Carolina, Tennessee
2024-03-26
Active, closed
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
NCT06218914Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer
AstraZeneca
Phase 1
108
California, Florida, Illinois, Kansas, Missouri, New York, Pennsylvania, Tennessee
2024-03-22
Recruiting
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
NCT06150664Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma
Compass Therapeutics
Phase 1
85
Alabama, California, Florida, Georgia, Indiana, Massachusetts, New York, Tennessee
2024-03-19
Active, closed
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
NCT06105021Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor
Affini-T Therapeutics, Inc.
Phase 1/2
100
California, Connecticut, New York, Oregon, Tennessee, Texas, Washington, Wisconsin
2024-03-06
Active, closed
A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
NCT06239116Hypothalamic Obesity, Prader-Willi Syndrome, PWS
Rhythm Pharmaceuticals, Inc.
Phase 1/2
111
Alabama, Illinois, Massachusetts, Tennessee, Texas, Utah
2024-03-05
Active, closed
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
NCT06239467Advanced Cancer, Breast Cancer, Advanced Solid Tumors, PI3K Gene Mutation
OnKure, Inc.
Phase 1
200
California, Colorado, Massachusetts, Nevada, New York, Tennessee, Virginia, Washington
2024-02-26
Recruiting
ParVation Therapeutics, Inc.
Phase 1
400
Connecticut, Pennsylvania, Tennessee, Texas, Utah
2024-02-23
Recruiting
OnCusp Therapeutics, Inc.
Phase 1
263
Colorado, Connecticut, Florida, Massachusetts, Michigan, New York, Oklahoma, Tennessee
2024-02-09
Recruiting
Novartis Pharmaceuticals
Observational
40
California, Colorado, District of Columbia, North Carolina, Ohio, Tennessee, Texas
2024-02-06
Recruiting
Quanta Therapeutics
Phase 1
250
California, Colorado, Connecticut, Florida, New York, North Carolina, Oklahoma, Tennessee
2024-02-05
Recruiting
Boehringer Ingelheim
Phase 1
20
California, Tennessee
2024-01-30
Active, closed
BicycleTx Limited
Phase 2
375
Colorado, Florida, Kansas, Kentucky, Nebraska, New York, South Carolina, Tennessee
2024-01-24
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
187
Alabama, California, Colorado, Connecticut, Florida, Massachusetts, New York, Tennessee
2024-01-23
Active, closed
PhotoniCare, Inc.
Observational
700
District of Columbia, Florida, New York, Oregon, South Carolina, Tennessee
2024-01-10
Active, closed
RECORDATI GROUP
Phase 2
93
California, Illinois, Louisiana, Maryland, Massachusetts, Minnesota, New York, Tennessee
2024-01-04
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
124
Indiana, New York, North Carolina, Ohio, Tennessee
2024-01-03
Recruiting
Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma
NCT06118086Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma
Remix Therapeutics
Phase 1/2
125
California, Florida, Massachusetts, Michigan, New York, Tennessee, Texas
2023-12-20
Active, closed
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
NCT06046222Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
NS Pharma, Inc.
Phase 2
45
Colorado, Minnesota, Ohio, Pennsylvania, South Carolina, Tennessee
2023-12-20
Recruiting
A Study of JNJ-87890387 for Advanced Solid Tumors
NCT06178614Neoplasms, Advanced Solid Tumors
Janssen Research & Development, LLC
Phase 1
200
Michigan, Tennessee
2023-12-14
Recruiting
Georgiamune Inc
Phase 1/2
111
California, Florida, Kentucky, New Jersey, Tennessee, Texas, Virginia
2023-12-12
Active, closed
Hoffmann-La Roche
Phase 1
30
Tennessee
2023-12-11
Active, closed
AstraZeneca
Phase 1/2
55
Missouri, Rhode Island, Tennessee, Texas
2023-12-05
Recruiting
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
BeOne Medicines
Phase 1
433
Colorado, Florida, Michigan, North Carolina, Ohio, Tennessee, Texas
2023-12-01
Active, closed
Genentech, Inc.
Phase 1
65
Alabama, Connecticut, New York, Ohio, Pennsylvania, Tennessee
2023-11-27
By invitation
InMode MD Ltd.
Not applicable
32
California, Tennessee
2023-11-10
Recruiting
A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
NCT06075810Breast Cancer, Breast Neoplasm, Breast Cancer Stage IV
MBQ Pharma
Phase 1
48
California, Florida, Tennessee
2023-11-09
Active, closed
Kite, A Gilead Company
Phase 1
21
Florida, Illinois, Tennessee, Texas, Washington
2023-11-09
Recruiting
Jazz Pharmaceuticals
Phase 1
177
California, Colorado, Florida, North Carolina, Pennsylvania, Tennessee, Texas, Virginia
2023-11-07
Recruiting
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
NCT05862012Relapsed/Refractory Multiple Myeloma
Ichnos Sciences SA
Phase 1
200
California, Florida, Georgia, Illinois, Massachusetts, New York, North Carolina, Tennessee
2023-11-01
Recruiting
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
NCT06047379Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer
Neonc Technologies, Inc.
Phase 1/2
134
California, Florida, Massachusetts, Tennessee, Texas, Washington
2023-11-01
Recruiting
Femasys Inc.
Not applicable
573
Arizona, California, Georgia, Idaho, New York, Ohio, Tennessee, Texas
2023-10-31
Recruiting
VALOR: Vaginal Atrophy & Long-term Observation of Recovery
NCT05953090Atrophic Vaginitis, Vaginal Atrophy, Genitourinary Syndrome of Menopause, Lichen Sclerosus of Vulva
Stratpharma AG
Not applicable
2,000
Alabama, California, Florida, Georgia, Nevada, North Carolina, South Carolina, Tennessee
2023-10-30
Active, closed
Chengdu Origen Biotechnology Co., Ltd.
Phase 1
25
Arizona, Illinois, Massachusetts, Nevada, New Jersey, Tennessee, Texas
2023-10-16
Active, closed
Gilead Sciences
Phase 1
45
Connecticut, Tennessee, Texas
2023-10-09
Recruiting
LigaChem Biosciences, Inc.
Phase 1/2
300
California, Massachusetts, Michigan, Tennessee, Texas
2023-10-05
Active, closed
Brain Neurotherapy Bio, Inc.
Phase 1
9
California, Florida, Massachusetts, Michigan, New York, Ohio, Tennessee
2023-10-03
Active, closed
First in Human Study of TORL-3-600 in Participants With Advanced Cancer
NCT05948826Advanced Solid Tumor, Colorectal Cancer
TORL Biotherapeutics, LLC
Phase 1
70
California, Colorado, Indiana, Missouri, Tennessee, Texas
2023-09-29
Recruiting
Pierre Fabre Medicament
Phase 1/2
345
California, North Carolina, Pennsylvania, Tennessee, Texas, Utah, Virginia
2023-09-26
Active, closed
A Study of ADRX-0706 in Select Advanced Solid Tumors
NCT06036121Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer
Adcentrx Therapeutics
Phase 1
144
California, Florida, Michigan, Ohio, Oklahoma, Tennessee, Texas, Utah
2023-09-26
Active, closed
Treatment of PAF With the Synaptic System
NCT05905835Paroxysmal Atrial Fibrillation
Synaptic Medical Corporation
Not applicable
128
Arizona, Arkansas, California, Missouri, New York, Tennessee, Texas, Virginia
2023-09-20
Recruiting
Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss
NCT05821959Sensorineural Hearing Loss, Bilateral
Eli Lilly and Company
Phase 3
48
California, Iowa, Massachusetts, Ohio, Pennsylvania, Tennessee
2023-09-15
Recruiting
IKS014 in Advanced Solid Tumors That Express HER2
NCT05872295Breast Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
Iksuda Therapeutics Ltd.
Phase 1
165
California, Massachusetts, Tennessee, Texas
2023-09-14
Recruiting
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
NCT06034275Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, High-risk Myelodysplastic Syndrome
Vincerx Pharma, Inc.
Phase 1
36
Alabama, Ohio, Tennessee, Texas, Washington
2023-09-13
Active, closed
Cryosa, Inc.
Not applicable
25
Colorado, Florida, Illinois, Louisiana, New York, Pennsylvania, Tennessee, Texas
2023-09-12
Active, closed
Perform® Humeral System - Fracture Study (PFX)
NCT05773352Traumatic Arthropathy of Shoulder, Fracture Humerus, Traumatic Arthritis, Revision of Other Devices if Sufficient Bone Stock Remains
Stryker Trauma and Extremities
Observational
118
Arizona, Arkansas, California, Florida, Illinois, Missouri, Tennessee, Texas
2023-08-31
Recruiting
AviadoBio Ltd
Phase 1/2
18
Ohio, Tennessee, Texas
2023-08-30
Recruiting
DualityBio Inc.
Phase 1/2
1,000
California, Florida, Georgia, Massachusetts, Michigan, New Jersey, Ohio, Tennessee
2023-08-17
Recruiting
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
NCT05967689Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Taiho Oncology, Inc.
Phase 2
220
Alabama, California, Massachusetts, Nevada, New Jersey, New York, Ohio, Tennessee
2023-07-31
Recruiting
Vividion Therapeutics, Inc.
Phase 1
290
Florida, Minnesota, Tennessee, Texas, Virginia
2023-07-28
Recruiting
D3 Bio (Wuxi) Co., Ltd
Phase 1/2
67
Michigan, New York, Tennessee, Texas
2023-07-10
Active, closed
IDEAYA Biosciences
Phase 2
160
Arizona, California, Florida, Michigan, Minnesota, New York, Pennsylvania, Tennessee
2023-07-03
Recruiting
River 2 Renal Corp.
Phase 2
95
California, Georgia, Massachusetts, Minnesota, Pennsylvania, Tennessee, Texas
2023-06-30
Recruiting
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
NCT05898399Advanced Solid Tumor, Metastatic Solid Tumor
Artios Pharma Ltd
Phase 1/2
181
Michigan, New York, Oklahoma, Pennsylvania, Tennessee, Texas
2023-06-30
Active, closed
Myopia Control Spectacle Lens Cessation Study
NCT05893979Myopia, Myopia Progression, Juvenile Myopia
SightGlass Vision, Inc.
Not applicable
90
California, Florida, Kansas, Missouri, New York, Tennessee, Texas, Utah
2023-06-23
Recruiting
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
NCT05780034Relapsed/Refractory B-cell Malignancies
Accutar Biotechnology Inc
Phase 1
60
Colorado, Florida, North Carolina, Ohio, Oregon, Tennessee, Texas, Washington
2023-06-20
Active, closed
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
NCT05887492Non Small Cell Lung Cancer, Solid Tumors, Adult, Lung Cancer, Lung Adenocarcinoma
Tango Therapeutics, Inc.
Phase 1/2
126
California, Colorado, Florida, Massachusetts, Michigan, New York, Tennessee, Texas
2023-06-12
Recruiting
Conjupro Biotherapeutics, Inc.
Phase 1
132
California, Colorado, Florida, New Hampshire, Pennsylvania, Tennessee, Texas, Virginia
2023-06-06
Recruiting
A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer
NCT05930210Diabetic Foot Ulcer, Foot Ulcer, Diabetes Mellitus, Wound
Energenesis Biomedical Co., Ltd.
Phase 3
230
Florida, Georgia, Tennessee, Texas, Utah, Virginia
2023-05-30
Recruiting
Tango Therapeutics, Inc.
Phase 1/2
225
California, Colorado, Florida, Illinois, Massachusetts, Michigan, New York, Tennessee
2023-05-26
Recruiting
Chugai Pharmaceutical
Phase 1
209
Pennsylvania, Rhode Island, Tennessee, Texas, Virginia
2023-05-24
Active, closed
Lantheus Medical Imaging
Observational
500
Alabama, Arkansas, California, Michigan, Missouri, Nebraska, Pennsylvania, Tennessee
2023-05-22
By invitation
G7 Freedom Constrained Vivacit-E Liners
NCT05587244Osteoarthritis, Hip, Rheumatoid Arthritis, Non-Union Fracture, Trochanteric Fractures
Zimmer Biomet
Not applicable
202
Alabama, California, Florida, New Jersey, Ohio, Tennessee, Texas, Utah
2023-05-08
Active, closed
Novartis Pharmaceuticals
Phase 1
71
California, Florida, Illinois, Maryland, Massachusetts, Minnesota, New York, Tennessee
2023-05-08
Active, closed
Legend Biotech USA Inc
Phase 1
56
Florida, Michigan, New Jersey, New York, North Carolina, Oregon, Tennessee, Washington
2023-04-18
Recruiting
Pounce™ Thrombectomy System Retrospective Registry
NCT05868161Peripheral Arterial Disease, Acute Limb Ischemia
SurModics, Inc.
Observational
500
Illinois, Indiana, Louisiana, Minnesota, Ohio, South Carolina, South Dakota, Tennessee
2023-04-18
Active, closed
Praxis Precision Medicines
Phase 1/2
60
Tennessee
2023-04-13
Active, closed
A Rollover Study of CC-122
NCT05688475Non-Hodgkin Lymphoma
Bristol-Myers Squibb
Phase 1
12
New York, Tennessee, Wisconsin
2023-04-11
Active, closed
GlaxoSmithKline
Phase 2
154
California, New Mexico, New York, Pennsylvania, Tennessee, Texas, Virginia
2023-04-03
Recruiting
Vega Therapeutics, Inc
Phase 1/2
116
California, Colorado, Georgia, North Carolina, Pennsylvania, Tennessee, Texas, Washington
2023-03-16
Active, closed
ModernaTX, Inc.
Phase 1
186
California, District of Columbia, Illinois, Louisiana, North Carolina, Rhode Island, South Carolina, Tennessee
2023-02-15
Recruiting
Merck Sharp & Dohme LLC
Phase 2
42
California, Colorado, District of Columbia, Ohio, Pennsylvania, Tennessee, Washington, Wisconsin
2023-01-19
Recruiting
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
NCT05573126Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer
Ellipses Pharma
Phase 1/2
95
Connecticut, Florida, Massachusetts, Michigan, Tennessee, Texas, Virginia
2023-01-11
Recruiting
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
NCT05592626Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm
Marengo Therapeutics, Inc.
Phase 1/2
366
California, Florida, Kansas, Maryland, Massachusetts, Michigan, Ohio, Tennessee
2023-01-04
Active, closed
Accutar Biotechnology Inc
Phase 1
100
Colorado, Florida, Maryland, Tennessee, Texas, Virginia, Washington
2022-12-29
By invitation
Tolmar Inc.
Phase 3
250
California, Florida, Kentucky, Maryland, New York, North Carolina, Pennsylvania, Tennessee
2022-12-28
Active, closed
Study of CHS-114 in Participants With Advanced Solid Tumors
NCT05635643Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
Coherus Oncology, Inc.
Phase 1
87
California, Georgia, Kentucky, Maryland, Michigan, Missouri, Ohio, Tennessee
2022-12-15
Active, closed
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
NCT05565417Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma
Immunitas Therapeutics
Phase 1/2
67
Arizona, Colorado, Florida, Oklahoma, Oregon, Tennessee, Texas, Virginia
2022-11-28
Rows per page Showing 1–500 of 692
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 21 November 2026. https://priyalifescience.com/clinical-trials-usa/state/tennessee

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,148 studies in total at the last sync on 21 Nov 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 692 of those studies with a site in Tennessee.

How many clinical trials are recruiting in Tennessee?

382 of the 692 studies on this page are recruiting new participants as of the 21 Nov 2026, 03:16 UTC sync. A further 19 have not yet opened recruitment, 269 are active but closed to new participants, and 22 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Tennessee), 692 studies
PhaseStudiesRecruitingShare
Phase 121212330.6%
Phase 1/21379319.8%
Phase 21135716.3%
Phase 3873612.6%
Not applicable63309.1%
Observational61328.8%
Phase 41071.4%
Phase 2/3941.3%

Most active sponsors

Lead sponsors with the most studies (Tennessee)
Lead sponsorStudiesRecruiting
AstraZeneca286
Novartis Pharmaceuticals188
Hoffmann-La Roche177
Pfizer149
AbbVie139
Merck Sharp & Dohme LLC1312
GlaxoSmithKline126
Janssen Research & Development, LLC126
Amgen105
Daiichi Sankyo94
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.